<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883480</url>
  </required_header>
  <id_info>
    <org_study_id>SLAT</org_study_id>
    <nct_id>NCT00883480</nct_id>
  </id_info>
  <brief_title>Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma</brief_title>
  <acronym>SLAT</acronym>
  <official_title>Tratamiento Individualizado en funci칩n de Las Mutaciones en EGFR y Del Nivel de expresi칩n de BRCA1 en Pacientes Con Adenocarcinoma de pulm칩n Avanzado</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung&#xD;
      adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacogenomic study, prospective, multicenter. Individualized treatment based on EGFR&#xD;
      mutations and level of BRCA1 expression in patients with advanced lung adenocarcinoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumoral Response (RECIST criteria)</measure>
    <time_frame>From date of end of experimental treatment until the date of last follow up, assessed up to 24 months]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/day 1 x 4 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel-Cisplatin</intervention_name>
    <description>Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine-Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/ day 1 x 4 cycles&#xD;
Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg/day x 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 18 years or more.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of non-small-cell lung carcinoma.(and&#xD;
             indifferentiated and BAC histology).&#xD;
&#xD;
               -  Only patients with advanced disease, defined as stage IV or IIIB with/without&#xD;
                  pleural effusion, will be included.&#xD;
&#xD;
               -  Tumor sample available.&#xD;
&#xD;
               -  A measurable lesion, as defined by RECIST criteria.&#xD;
&#xD;
               -  Karnofsky score 60% or more (ECOG &lt; 2).&#xD;
&#xD;
               -  Patients should not have received previous treatment with chemotherapy or other&#xD;
                  agents for disseminated disease. Chemotherapy is allowed if the initial diagnosis&#xD;
                  of the patient is limited disease and the patient has received adjuvant or&#xD;
                  neoadjuvant treatment.&#xD;
&#xD;
          -  Patients with cerebral disease are permitted, without any time limitations after&#xD;
             holocranial irradiation or complementary antiedema treatment.&#xD;
&#xD;
          -  Patients with hepatical, renal and hematology normality values.&#xD;
&#xD;
          -  Patients should sign an informed consent form before inclusion in the study that&#xD;
             specifies that the clinical trial treatment entails consent for the analysis of&#xD;
             biological samples of tumor and blood.&#xD;
&#xD;
          -  Patients of childbearing age of either sex must use effective contraceptive methods&#xD;
             (barrier methods or other birth control methods) before entering the study and while&#xD;
             participating in the study.&#xD;
&#xD;
          -  Patients must be available for clinical follow-up..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received an investigational medicinal product in the 21 days before&#xD;
             inclusion in the study or antiEGFR receptor agent.&#xD;
&#xD;
          -  Severe comorbidity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Rosell, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>ICO-HOSPITAL GERMANS TRIAS I PUJOL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ico-Hospital Universitarios Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>M치laga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

